Systematic (IUPAC) name | |
---|---|
4-[(dichloroacetyl)(methyl)amino]phenyl furan-2-carboxylate | |
Clinical data | |
Trade names | Entamide |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy cat. | No available data |
Legal status | Not approved (US, CA) |
Routes | Oral |
Pharmacokinetic data | |
Bioavailability | 90% (diloxanide) |
Metabolism | Hydrolyzed to furoic acid and diloxanide, which undergoes extensive glucuronidation |
Half-life | 3 hours |
Excretion | Renal (90%), fecal (10%) |
Identifiers | |
CAS number | 3736-81-0 |
ATC code | P01AC01 |
PubChem | CID 19529 |
DrugBank | DB08792 |
ChemSpider | 18400 |
KEGG | D02480 |
ChEMBL | CHEMBL1334860 |
Chemical data | |
Formula | C14H11Cl2NO4 |
Mol. mass | 328.147 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Diloxanide furoate is an anti-protozoal drug used in the treatment of Entamoeba histolytica[1] and some other protozoal infections.
A 13-year study conducted by the United States Center for Disease Control between 1977 and 1990 found that this drug had a low incidence of side effects and was successful in treatment of 86% of asymptomatic carriers of Entamoeba histolytica. [2]
United States: Not currently approved for use. A CDC study authorized the use of this drug in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990. [2]
|